Skip to main content

Efavirenz News

Mylan Introduces Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Triple Combo Once-Daily HIV Treatment in the U.S.

HERTFORDSHIRE, England and PITTSBURGH, March 28, 2018 /PRNewswire/ – Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will introduce in the U.S. a third cost-saving HIV...

Mylan Introduces Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Triple Combo Once-Daily HIV Treatment in the U.S.

HERTFORDSHIRE, England and PITTSBURGH, March 28, 2018 /PRNewswire/ – Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will introduce in the U.S. a third cost-saving HIV...

Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of Sustiva (efavirenz) in HIV-1 Infected Pediatric Patients

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Sustiva...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

HIV Infection

Efavirenz patient information at Drugs.com